ARA290 + NAD+ Research Data

Natural Aminos Research Stack or Formula of the Day

ARA290 + NAD+

Innate Repair Signaling + Cellular Bioenergetics / Neuropathy Research Spotlight

Compound Identity & Current Evidence Context

ARA290, also called cibinetide or pyroglutamate helix-B surface peptide (pHBSP), is an 11-amino-acid peptide engineered from the three-dimensional structure of erythropoietin. It was designed to activate the injury-induced innate repair receptor, a heteromeric receptor involving the erythropoietin receptor and the beta-common receptor (CD131), without activating the classical erythropoietic receptor strongly enough to stimulate red-cell production. Experimental and early human work has focused primarily on tissue protection, inflammation control, neuropathic pain, and small-fiber nerve repair.

Human ARA290 evidence is real but limited in scale. Randomized studies in sarcoidosis-associated small-fiber neuropathy and a Phase II study in type 2 diabetes with painful neuropathy reported improvements in selected neuropathic symptoms and, in some studies, objective corneal small-nerve-fiber measures. A 64-subject Phase IIb sarcoidosis trial found a statistically significant increase in corneal nerve fiber area at the 4 mg study dose, while pain improved in all groups and the placebo-corrected pain comparison did not reach conventional statistical significance. These findings support a biologic nerve-repair signal, but they do not establish broad efficacy for every neuropathy or chronic pain condition.

NAD+ (nicotinamide adenine dinucleotide) is an endogenous redox cofactor and signaling substrate required for mitochondrial energy metabolism, DNA-repair enzymes such as PARPs, sirtuin activity, and numerous cellular stress-response pathways. The scientific literature on “NAD boosting” is much larger than the literature on direct NAD+ administration, but those are not interchangeable evidence categories. Most human intervention data involve precursors such as nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide, or nicotinic acid rather than intravenous or injected NAD+ itself.

A 2026 PRISMA-guided systematic review identified 33 human NAD-related intervention studies and concluded that NR and NMN reliably increase circulating or cellular NAD-related metabolites and are generally well tolerated over weeks to months, while functional, metabolic, vascular, and healthspan outcomes remain heterogeneous and often null or endpoint-specific. Importantly, that review found no eligible clinical outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness purposes. A small human pharmacokinetic pilot of direct IV NAD+ and a 2026 retrospective commercial-setting tolerability study provide limited direct-infusion information, not proof of broad clinical benefit.

No peer-reviewed human, animal, or cell study was identified that directly tested ARA290/cibinetide together with NAD+ as a defined combination. The stack must therefore be evaluated from the separate evidence bases and from mechanistic theory rather than demonstrated combination efficacy.

Benefits

ARA290 / Cibinetide

The strongest human signal for ARA290 is in small-fiber neuropathy. In a 22-patient randomized double-blind sarcoidosis pilot, four weeks of ARA290 improved the Small Fiber Neuropathy Screening List score compared with placebo and produced favorable changes in selected quality-of-life domains. A separate blinded trial using daily subcutaneous dosing reported improvement in neuropathic symptoms together with increased corneal small-nerve-fiber density, altered temperature sensitivity, and improved six-minute walk performance.

The later 64-subject Phase IIb trial strengthened the objective nerve-fiber finding. The 4 mg study group showed a significant placebo-corrected increase in corneal nerve fiber area, and regenerating intraepidermal GAP-43-positive fibers also increased. This is important because it moves the evidence beyond symptom reporting toward a measurable structural marker of small-fiber repair. However, dose response was not linear, the trial lasted only 28 days, and pain outcomes were less definitive than the nerve-fiber endpoint.

In type 2 diabetes with painful neuropathy, a Phase II study reported improved PainDetect scores, selected metabolic markers, and increased corneal nerve fiber density in participants with reduced baseline density. These data are encouraging but remain small, short-duration, and insufficient to establish ARA290 as a proven disease-modifying therapy for diabetic neuropathy.

Preclinical studies support the proposed mechanism. ARA290 has reduced mechanical and cold allodynia in nerve-injury models, suppressed spinal microglial activation, reduced inflammatory injury, and promoted nerve regeneration/remyelination in experimental autoimmune neuritis. The major scientific attraction is that it attempts to retain erythropoietin-like tissue-protective signaling without the hematopoietic risks of full erythropoietin.

NAD+ / NAD-Boosting Biology

The clearest benefit supported in humans is biochemical target engagement from NAD precursors: NR and NMN repeatedly increase circulating or cellular NAD-related metabolites. A randomized 65-person study reported that both NR and NMN increased circulating NAD+ after 14 days, whereas nicotinamide did not produce the same response. Randomized NMN studies and meta-analyses generally support short-term tolerability and NAD-level increases, but clinical metabolic and performance outcomes are inconsistent.

Direct IV NAD+ evidence is much thinner. A pilot study in healthy men characterized plasma and urinary NAD-related metabolites during a six-hour IV NAD+ infusion, demonstrating that administered NAD+ is metabolized and excreted in measurable ways. A 2026 retrospective real-world study found that IV NAD+ commonly produced infusion-related gastrointestinal symptoms, increased heart rate, and chest pressure that resolved after infusion; standard short-term safety markers showed no major deterioration, but clinical effectiveness was not established.

For neuropathy specifically, the most relevant evidence comes from NAD metabolism and precursor studies rather than direct NAD+ treatment. In diabetic-neuropathy animal models, NR and NMN restored NAD+ and SIRT1 activity in dorsal-root-ganglion neurons, improved sensory function and nerve conduction, and preserved or restored intraepidermal nerve fibers. Related experimental work links the NAD+-dependent SIRT1/PGC-1alpha/TFAM pathway to mitochondrial function and axonal maintenance. These findings create a plausible nerve-energy and regeneration rationale, but they remain preclinical for the exact intervention “direct NAD+ plus ARA290.”

What the Formulas Are Studied For

ARA290 Research Areas

Sarcoidosis-associated small-fiber neuropathy and neuropathic symptoms.

Diabetic peripheral neuropathy and painful neuropathy.

Corneal small-nerve-fiber regeneration as a disease-modification biomarker.

Innate repair receptor signaling involving EPOR/CD131.

Neuroinflammation, microglial activation, allodynia, and nerve-injury repair.

Experimental autoimmune neuritis, remyelination, macrophage signaling, and Schwann-cell biology.

Tissue-protection signaling designed to avoid classical erythropoietic stimulation.

NAD+ / NAD-Boosting Research Areas

Cellular redox reactions and mitochondrial ATP-generating metabolism.

Sirtuin signaling, DNA repair, PARP activity, and cellular stress responses.

Age-related NAD decline and attempts to restore NAD pools with NR, NMN, nicotinamide, or nicotinic acid.

Metabolic health, glucose and lipid regulation, vascular function, exercise/physical performance, and healthy-aging hypotheses.

Experimental diabetic neuropathy, axonal maintenance, mitochondrial function, and SIRT1-dependent nerve regeneration.

Direct IV NAD+ pharmacokinetics and short-term infusion tolerability; direct clinical outcomes evidence remains sparse.

Published Research - Worldwide Evidence Review

ARA290 / Cibinetide - Netherlands, United States and International Neuropathy Programs

The early human ARA290 neuropathy program was strongly associated with Leiden University Medical Center in the Netherlands. The 2012 randomized pilot in 22 sarcoidosis patients with small-fiber-neuropathy symptoms found a significant improvement in the SFNSL symptom score compared with placebo after four weeks. This was followed by a blinded study reporting increased corneal nerve fiber density and improvements in sensory and functional measures after daily subcutaneous treatment.

The subsequent Phase IIb study enrolled 64 subjects and included investigators from the Cleveland Clinic and U.S. academic centers, Leiden in the Netherlands, the University of Manchester in the United Kingdom, and Weill Cornell Medicine-Qatar. The 4 mg group showed a statistically significant increase in corneal nerve fiber area compared with placebo, with associated increases in regenerating skin nerve fibers. The multicountry investigator network and objective imaging endpoints make this one of the strongest pieces of ARA290 evidence, although it remains a short, modest-sized trial.

In type 2 diabetes, Phase II research reported improved neuropathic symptoms and selected metabolic measures and a corneal nerve-fiber signal. These results align with the sarcoidosis studies but do not yet constitute a large confirmatory Phase III program. The ClinicalTrials.gov sarcoidosis study record identifies ARA290 as cibinetide/pHBSP and documents randomized placebo-controlled subcutaneous evaluation, but no approved indication follows from trial registration or a substance identifier alone.

NAD+ - Global Human Precursor Evidence and Limited Direct-Infusion Research

Human NAD-augmentation research spans multiple countries and intervention types. Modern randomized studies of NR and NMN generally show that these precursors can increase blood or cellular NAD-related metabolites. A 2026 systematic review covering 33 human interventions found consistent biochemical target engagement but heterogeneous or null results across many functional, metabolic, and vascular endpoints. This is the correct high-level interpretation: NAD biology is strong, but broad clinical benefit is not established simply because NAD levels rise.

Meta-analyses reinforce the need to separate different precursors. A 2024 analysis of NMN randomized trials found that NMN increased blood NAD levels but did not establish uniform improvements across glucose and lipid outcomes. Broader precursor meta-analyses are heavily influenced by nicotinic acid and other vitamin B3 forms, which have pharmacology that should not automatically be attributed to NR, NMN, or direct NAD+ infusion.

Direct intravenous NAD+ human research remains sparse. The 2019 pharmacokinetic pilot administered 750 mg IV NAD+ over six hours to eight healthy men, with three saline controls, and described delayed changes in plasma metabolites and urinary excretion. A 2026 retrospective study of commercially administered IV NAD+ versus IV NR reported substantially more infusion symptoms with NAD+, including gastrointestinal symptoms, increased heart rate, and chest pressure, while routine short-term laboratory markers did not show major deterioration. Neither study establishes neuropathy repair or durable clinical benefit.

Direct Research on ARA290 + NAD+ Together

No peer-reviewed trial, prospective observational study, animal experiment, or cell study was identified that administered ARA290/cibinetide together with NAD+ as a defined intervention. No evidence was identified showing that NAD+ changes ARA290 pharmacokinetics, innate repair receptor activation, corneal nerve-fiber response, pain outcomes, or safety. Likewise, no study shows that ARA290 alters NAD metabolism, sirtuin activity, mitochondrial NAD pools, or the clinical response to NAD augmentation. Any claim of synergy is therefore mechanistic theory, not demonstrated combination evidence.

Theory of the Stack - How the Combination Could Work

1. Injury-Sensing and Repair Signaling - ARA290 Layer. ARA290 would provide the injury-responsive signaling layer. Its proposed receptor system is induced by tissue injury and inflammation, and activation is associated with anti-inflammatory, anti-apoptotic, and repair programs without the classical red-cell stimulation of erythropoietin. In neuropathy research, this layer is supported by human symptom and small-fiber imaging data.

2. Cellular Energy and Redox Capacity - NAD Layer. NAD+ is essential for mitochondrial redox reactions, ATP-related metabolism, sirtuin signaling, and DNA-repair processes. In theory, a damaged or metabolically stressed sensory neuron may require adequate NAD metabolism to sustain axonal maintenance and regeneration. This rationale is strongest from precursor and animal work, not direct IV NAD+ outcomes trials.

3. The Mechanisms Are Potentially Complementary. ARA290 and NAD biology do not primarily target the same receptor or pathway. ARA290 is an extracellular injury-repair receptor agonist; NAD is a central intracellular metabolic cofactor and signaling substrate. On paper, reducing a damaging inflammatory environment while supporting mitochondrial and axonal energy biology is more complementary than redundant.

4. Neuropathy Is the Most Coherent Research Context. The overlap between the evidence bases is most scientifically coherent in peripheral nerve injury or diabetic/small-fiber neuropathy. ARA290 has human small-fiber data, while experimental NAD-precursor research shows restoration of nerve conduction, sensory function, and intraepidermal fibers in diabetic animals. This creates a testable repair-plus-bioenergetics hypothesis.

5. Direct NAD+ Is the Major Translational Uncertainty. NAD+ precursor studies cannot automatically validate injected or infused NAD+. Extracellular NAD+ is metabolized, cellular entry is complex, and direct IV studies have not established that tissue NAD pools or clinical nerve outcomes improve in the same way as precursor interventions. The exact NAD formulation and route therefore matter greatly.

6. Timing Could Matter More Than Simple Co-Administration. Tissue repair evolves through inflammation, cellular stress responses, mitochondrial adaptation, axonal growth, and remodeling. ARA290 may influence inflammatory/repair signaling while NAD-dependent pathways may influence cellular energy and stress adaptation. Whether simultaneous exposure is optimal, unnecessary, or even biologically mismatched has never been tested.

7. The Stack Could Be Dominated by ARA290 Evidence in Neuropathy. Because ARA290 already has direct human neuropathy data while NAD+ itself does not, any observed improvement in an uncontrolled combination setting could easily be attributed to ARA290, placebo response, natural fluctuation, or other factors. A controlled ARA290-alone arm would be essential to establish incremental NAD benefit.

8. Biomarker Changes Would Not Equal Clinical Benefit. Increasing circulating NAD-related metabolites or altering inflammatory markers would be biologically interesting but would not prove meaningful nerve regeneration or symptom relief. Objective endpoints should include corneal confocal microscopy, intraepidermal nerve-fiber density, nerve conduction where applicable, validated neuropathy scores, quantitative sensory testing, and functional outcomes.

9. Potential Conflicts Are Not Well Defined. ARA290 has a very short plasma half-life yet can trigger longer-lived signaling. Direct IV NAD+ can cause acute infusion symptoms. No pharmacokinetic or safety-interaction study has evaluated the pair. It is therefore not possible to assume that adding NAD+ is neutral simply because the mechanisms appear complementary.

10. The Best Scientific Question Is Incremental Disease Modification. Rather than asking whether the stack “boosts recovery” generally, the stronger research question is whether NAD augmentation adds measurable nerve structural or functional improvement beyond ARA290 alone, and whether any added effect depends on baseline metabolic dysfunction or NAD depletion.

Possible Overall Benefit - Theoretical, Not Proven

The most defensible theoretical benefit of ARA290 + NAD+ is a two-level peripheral-nerve repair strategy. ARA290 could theoretically reduce injury-associated inflammatory signaling and activate tissue-protective repair pathways through the innate repair receptor, while improved NAD availability could support mitochondrial metabolism, SIRT1-linked stress responses, and the energetic demands of axonal maintenance and regrowth.

This theory is strongest for small-fiber or metabolically associated neuropathy because the two evidence streams partially converge there: ARA290 has human small-fiber regeneration signals, and NAD-precursor studies have repaired experimental diabetic neuropathy and restored intraepidermal fibers in animals. If the biology translated, a combination might theoretically improve the tissue environment and the energy capacity needed for repair at the same time.

The critical limitation is that the NAD component is not clinically equivalent to the ARA290 component. ARA290 has direct human neuropathy trials; direct NAD+ does not have comparable neuropathy outcomes trials. Therefore, the stack should be described as biologically complementary but clinically unvalidated, with the NAD contribution substantially more speculative than the ARA290 contribution.

Why More Research Is Needed

No published human, animal, or cell study was identified that directly tested ARA290/cibinetide + NAD+ together.

ARA290 human trials are relatively small, short, and focused on selected neuropathy populations rather than broad chronic pain or nerve disease.

The strongest ARA290 Phase IIb signal was an objective corneal nerve-fiber endpoint; pain outcomes were less definitive and placebo response was substantial.

Long-term ARA290 safety, durability of nerve regrowth, optimal treatment duration, and large confirmatory efficacy trials remain insufficiently characterized.

Most human “NAD boosting” evidence involves NR or NMN, not direct NAD+ administration.

Direct IV NAD+ has limited pharmacokinetic and short-term tolerability data and lacks robust randomized clinical outcomes trials for neuropathy, anti-aging, or general wellness.

It is unknown whether IV or other direct NAD+ administration meaningfully increases intracellular NAD in peripheral sensory neurons or Schwann cells in humans.

Experimental NAD biology is complex: NAD synthesis, NMN accumulation, sirtuins, PARPs, and axonal-degeneration pathways can have context-dependent effects, so “more NAD” is not automatically equivalent to better nerve repair.

No study has established pharmacokinetic, chemical, hemodynamic, or tolerability interactions between ARA290 and direct NAD+.

A rigorous future study would require placebo/control, ARA290-alone, NAD-strategy-alone, and combination arms to establish incremental benefit and distinguish synergy from independent effects.

Objective endpoints should include validated neuropathy scores, quantitative sensory testing, corneal nerve-fiber imaging, skin-biopsy intraepidermal fibers, functional measures, metabolic biomarkers, NAD metabolomics, and systematic adverse-event monitoring.

Research Summary

ARA290 + NAD+ is a mechanistically coherent but clinically untested nerve-repair and cellular-bioenergetics stack. ARA290/cibinetide has the stronger direct evidence: multiple small randomized human studies in sarcoidosis-associated small-fiber neuropathy and type 2 diabetes-associated neuropathy have reported symptom improvements and objective corneal small-nerve-fiber changes, with the 64-subject Phase IIb trial showing a significant corneal nerve-fiber-area increase in the 4 mg group. Preclinical work also supports anti-inflammatory and nerve-repair signaling through the innate repair receptor.

NAD+ biology is foundational to cellular metabolism and axonal health, and human NR/NMN trials consistently show that NAD-related metabolites can be increased. However, clinical outcomes from NAD precursors are heterogeneous, and direct IV NAD+ has only limited pharmacokinetic, tolerability, and exploratory data. The strongest neuropathy rationale for NAD augmentation comes from animal studies in which NR or NMN restored NAD/SIRT1 signaling, nerve conduction, sensory function, and intraepidermal fibers.

The stack has no direct evidence. The theoretical division of labor is plausible: ARA290 could improve the inflammatory and tissue-repair environment while NAD-related metabolic support could help sustain mitochondrial function and axonal regeneration. The concept is therefore worth studying, particularly in metabolically associated small-fiber neuropathy, but the current evidence cannot establish that direct NAD+ adds benefit to ARA290 or that the pair is synergistic.

Selected Sources

Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine. 2012;18:1430-1436. PMID: 23168581. DOI: 10.2119/molmed.2012.00332.

Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine. 2013. PMID: 24136731.

Brines M, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science. 2017;58:Bio52-Bio60. PMID: 28475703. DOI: 10.1167/iovs.16-21291.

Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2015. PMID: 25387363.

Swartjes M, et al. ARA 290, a peptide derived from erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain. 2014. PMID: 24529189.

Brines M, Cerami A. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacology & Therapeutics. 2015. PMID: 25728128.

ClinicalTrials.gov. NCT02039687. Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. Results posted 2017.

Grant R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. 2019;11:257. PMCID: PMC6751327.

Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026; DOI: 10.1016/j.arr.2026.103057. PMID: 41655607.

Reyna J, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. 2026. PMID: 41704678.

Das A, et al. NAD+ Precursors Repair Mitochondrial Function in Diabetes and Prevent Experimental Diabetic Neuropathy. 2022. PMID: 35563288.

Das A, et al. NAD+ Precursors Reverse Experimental Diabetic Neuropathy in Mice. 2024. PMID: 38256175.

Chandrasekaran K, et al. Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy. Brain. 2019. PMID: 31754701.

Chen F, et al. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports. 2024. PMID: 39531138.

FDA Global Substance Registration System. Cibinetide / ARA 290 substance record. FDA notes that UNII availability does not imply regulatory review or approval.

Theory vs. Proof - Verdict

What is supported by evidence: ARA290/cibinetide has direct randomized human evidence in sarcoidosis-associated small-fiber neuropathy and smaller type 2 diabetes neuropathy research, including objective corneal nerve-fiber changes and selected symptom improvements. ARA290 also has extensive preclinical evidence for innate repair receptor-mediated anti-inflammatory and tissue-protective signaling. NAD+ is essential for cellular redox metabolism and NAD-dependent signaling; human NR and NMN studies can raise NAD-related metabolites, and experimental NAD-precursor studies can improve diabetic neuropathy and nerve-fiber preservation in animals.

What is not proven: that direct NAD+ infusion or injection repairs human peripheral neuropathy; that direct NAD+ reproduces the neurologic effects seen with NR/NMN in animal models; that ARA290 is broadly effective across neuropathy etiologies; that adding NAD+ improves ARA290-associated nerve regeneration, pain, function, or metabolic outcomes; or that the combination is additive, synergistic, safer, or more durable than ARA290 alone.

Verdict - theory vs. proof: the mechanistic theory is moderately strong and genuinely complementary, but the clinical proof for the stack is absent. ARA290 supplies a targeted injury-repair and anti-inflammatory signaling pathway with a meaningful early human small-fiber evidence base. NAD supplies a biologically credible mitochondrial/redox and SIRT1-linked axonal-support concept, but the clinically relevant evidence is largely indirect because it comes from precursor studies and preclinical neuropathy models rather than direct NAD+ outcomes trials. Overall, ARA290 + NAD+ is best classified as a plausible nerve-repair plus bioenergetic hypothesis with moderate human evidence for ARA290, strong foundational but indirect NAD biology, limited direct NAD+ clinical evidence, and no demonstrated combination benefit.

Research & Educational Use Only !!